FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040486812> ?p ?o ?g. }

• W2040486812 endingPage "812" @default.
• W2040486812 startingPage "807" @default.
• W2040486812 abstract "Long-term survival and late toxicities of a randomized Phase II study of chemoradiotherapy for esophageal cancer were analyzed.Eligible patients were <75 years old and performance status 0-2, and had Stages II-IVA esophageal cancer. For arm A (short-term infusion), cisplatin 70 mg/m(2) Days 1 and 29 and 5-fluorouracil 700 mg/m(2) Days 1-5 and 29-33 were given concurrently with radiotherapy of 60 Gy/30 fr/7 weeks (1 week split). For arm B (protracted infusion), cisplatin 7 mg/m(2) Days 1-5, 8-12, 29-33 and 36-40, and 5-fluorouracil 250 mg/m(2) Days 1-14 and 29-42 were given with the same radiotherapy. Two cycles of consolidation cisplatin/5-fluorouracil chemotherapy were given to both arms.Between 2001 and 2006, 91 patients were enrolled; 46 were randomized to arm A, and 45 to arm B. The 2- and 5-year overall survival rates for arm A were 46 and 35% (95% confidence interval: 22-48%), while those for arm B were 44 and 22% (11-35%), respectively. Excluding four patients with early death, seven (17%) patients in arm A and eight (18%) in arm B showed late toxicities of Grade 3 or more. Most of the toxicities were cardiac or pleural toxicities. Patients with severe late toxicities often had coexistent hypothyroidism. There were three patients with a secondary malignancy possibly related to treatment.Low-dose protracted infusion chemotherapy with radiotherapy is not superior to full-dose short-term infusion chemotherapy with radiotherapy for esophageal cancer. Late toxicities, including cardiac and pleural toxicities, hypothyroidism and secondary malignancy, should be carefully monitored." @default.
• W2040486812 created "2016-06-24" @default.
• W2040486812 creator A5000171959 @default.
• W2040486812 creator A5000917216 @default.
• W2040486812 creator A5013014848 @default.
• W2040486812 creator A5015259799 @default.
• W2040486812 creator A5033390295 @default.
• W2040486812 creator A5043131068 @default.
• W2040486812 creator A5049584975 @default.
• W2040486812 creator A5057569242 @default.
• W2040486812 creator A5062565190 @default.
• W2040486812 creator A5068713233 @default.
• W2040486812 creator A5081145814 @default.
• W2040486812 date "2012-07-17" @default.
• W2040486812 modified "2023-09-29" @default.
• W2040486812 title "Long-term Follow-up of a Randomized Phase II Study of Cisplatin/5-FU Concurrent Chemoradiotherapy for Esophageal Cancer (KROSG0101/JROSG021)" @default.
• W2040486812 cites W1975128231 @default.
• W2040486812 cites W1997900832 @default.
• W2040486812 cites W2012874510 @default.
• W2040486812 cites W2017453832 @default.
• W2040486812 cites W2027185592 @default.
• W2040486812 cites W2030553697 @default.
• W2040486812 cites W2039612753 @default.
• W2040486812 cites W2044182241 @default.
• W2040486812 cites W2058106570 @default.
• W2040486812 cites W2067570309 @default.
• W2040486812 cites W2080870383 @default.
• W2040486812 cites W2086778710 @default.
• W2040486812 cites W2117223681 @default.
• W2040486812 cites W2119696360 @default.
• W2040486812 cites W2120518038 @default.
• W2040486812 cites W2144263975 @default.
• W2040486812 cites W2154107291 @default.
• W2040486812 cites W2171887862 @default.
• W2040486812 cites W2191838028 @default.
• W2040486812 doi "https://doi.org/10.1093/jjco/hys112" @default.
• W2040486812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22811410" @default.
• W2040486812 hasPublicationYear "2012" @default.
• W2040486812 type Work @default.
• W2040486812 sameAs 2040486812 @default.
• W2040486812 citedByCount "30" @default.
• W2040486812 countsByYear W20404868122013 @default.
• W2040486812 countsByYear W20404868122014 @default.
• W2040486812 countsByYear W20404868122015 @default.
• W2040486812 countsByYear W20404868122016 @default.
• W2040486812 countsByYear W20404868122017 @default.
• W2040486812 countsByYear W20404868122018 @default.
• W2040486812 countsByYear W20404868122019 @default.
• W2040486812 countsByYear W20404868122020 @default.
• W2040486812 countsByYear W20404868122021 @default.
• W2040486812 countsByYear W20404868122023 @default.
• W2040486812 crossrefType "journal-article" @default.
• W2040486812 hasAuthorship W2040486812A5000171959 @default.
• W2040486812 hasAuthorship W2040486812A5000917216 @default.
• W2040486812 hasAuthorship W2040486812A5013014848 @default.
• W2040486812 hasAuthorship W2040486812A5015259799 @default.
• W2040486812 hasAuthorship W2040486812A5033390295 @default.
• W2040486812 hasAuthorship W2040486812A5043131068 @default.
• W2040486812 hasAuthorship W2040486812A5049584975 @default.
• W2040486812 hasAuthorship W2040486812A5057569242 @default.
• W2040486812 hasAuthorship W2040486812A5062565190 @default.
• W2040486812 hasAuthorship W2040486812A5068713233 @default.
• W2040486812 hasAuthorship W2040486812A5081145814 @default.
• W2040486812 hasBestOaLocation W20404868121 @default.
• W2040486812 hasConcept C121608353 @default.
• W2040486812 hasConcept C126322002 @default.
• W2040486812 hasConcept C141071460 @default.
• W2040486812 hasConcept C2776694085 @default.
• W2040486812 hasConcept C2778239845 @default.
• W2040486812 hasConcept C2778336483 @default.
• W2040486812 hasConcept C2778424827 @default.
• W2040486812 hasConcept C2779742542 @default.
• W2040486812 hasConcept C2780456651 @default.
• W2040486812 hasConcept C509974204 @default.
• W2040486812 hasConcept C71924100 @default.
• W2040486812 hasConcept C90924648 @default.
• W2040486812 hasConceptScore W2040486812C121608353 @default.
• W2040486812 hasConceptScore W2040486812C126322002 @default.
• W2040486812 hasConceptScore W2040486812C141071460 @default.
• W2040486812 hasConceptScore W2040486812C2776694085 @default.
• W2040486812 hasConceptScore W2040486812C2778239845 @default.
• W2040486812 hasConceptScore W2040486812C2778336483 @default.
• W2040486812 hasConceptScore W2040486812C2778424827 @default.
• W2040486812 hasConceptScore W2040486812C2779742542 @default.
• W2040486812 hasConceptScore W2040486812C2780456651 @default.
• W2040486812 hasConceptScore W2040486812C509974204 @default.
• W2040486812 hasConceptScore W2040486812C71924100 @default.
• W2040486812 hasConceptScore W2040486812C90924648 @default.
• W2040486812 hasIssue "9" @default.
• W2040486812 hasLocation W20404868121 @default.
• W2040486812 hasLocation W20404868122 @default.
• W2040486812 hasOpenAccess W2040486812 @default.
• W2040486812 hasPrimaryLocation W20404868121 @default.
• W2040486812 hasRelatedWork W1975840453 @default.
• W2040486812 hasRelatedWork W2348325681 @default.
• W2040486812 hasRelatedWork W2363409655 @default.
• W2040486812 hasRelatedWork W2379292808 @default.
• W2040486812 hasRelatedWork W2394853503 @default.

• next